Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Gastrointestinal: Pancreas

Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

The purpose of this study is to find out how safe and tolerable the study drug INCB054329 is in patients with advanced types of cancer (including solid tumors and blood cancers). This study will mainly answer the following: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that enters and leaves the body over time and the effects it has on the body; 3) preliminary evidence of whether or not the drug has any anti-cancer effects.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Randomized Phase II Study of Cisplatin and Etoposide versus Tamozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancratic Neuroendocrine Carcinomas

The purpose of this study is to compare the effects (good and bad) of the study drugs temozolomide and capecitabine to cisplatin and etoposide, the drugs used for usual chemotherapy treatment for advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.

Status: Accepting New Patients
Principal Investigator: Halla Nimeiri

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus Nab-paclitaxel and Gemcitabine versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

This study has two purposed: to find out more about how safe and tolerable MM-141 is when given as a fixed-dose (as compared to a dose determined by a patient’s weight) and combined with nab-paclitaxel and gemcitabine, and to evaluate whether the combination of MM-141, nab-paclitaxel and gemcitabine works better against tumor cells than nab-paclitaxel and gemcitabine alone in subjects with metastatic pancreatic cancer.

Status: Accepting New Patients
Principal Investigator: Halla Nimeiri

A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

The purpose of this study is to see if the combination of temozolomide and pazopanib is safe as well as whether is it effective in improving outcomes.

Status: Accepting New Patients
Principal Investigator: Halla Nimeiri

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Wed - February 22, 2017 - 09:05 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.